These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 9039099)

  • 1. Antisense inhibition and adeno-associated viral vector delivery for reducing hypertension.
    Phillips MI
    Hypertension; 1997 Jan; 29(1 Pt 2):177-87. PubMed ID: 9039099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged reduction of high blood pressure with an in vivo, nonpathogenic, adeno-associated viral vector delivery of AT1-R mRNA antisense.
    Phillips MI; Mohuczy-Dominiak D; Coffey M; Galli SM; Kimura B; Wu P; Zelles T
    Hypertension; 1997 Jan; 29(1 Pt 2):374-80. PubMed ID: 9039130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attenuation of hypertension and heart hypertrophy by adeno-associated virus delivering angiotensinogen antisense.
    Kimura B; Mohuczy D; Tang X; Phillips MI
    Hypertension; 2001 Feb; 37(2 Pt 2):376-80. PubMed ID: 11230303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene therapy for hypertension: antisense inhibition with adeno-associated viral vector delivery targeting angiotensin II type 1-receptor messenger ribonucleic acid.
    Phillips MI
    Am J Cardiol; 1998 Nov; 82(10A):60S-62S. PubMed ID: 9860363
    [No Abstract]   [Full Text] [Related]  

  • 5. Gene therapy for hypertension: sense and antisense strategies.
    Phillips MI
    Expert Opin Biol Ther; 2001 Jul; 1(4):655-62. PubMed ID: 11727501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of cold-induced hypertension by antisense oligodeoxynucleotides to angiotensinogen mRNA and AT1-receptor mRNA in brain and blood.
    Peng JF; Kimura B; Fregly MJ; Phillips MI
    Hypertension; 1998 Jun; 31(6):1317-23. PubMed ID: 9622148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense inhibition of hypertension: a new strategy for renin-angiotensin candidate genes.
    Phillips MI; Wielbo D; Gyurko R
    Kidney Int; 1994 Dec; 46(6):1554-6. PubMed ID: 7700004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antisense inhibition of AT1 receptor mRNA and angiotensinogen mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin.
    Gyurko R; Wielbo D; Phillips MI
    Regul Pept; 1993 Dec; 49(2):167-74. PubMed ID: 8134617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatic gene therapy for hypertension.
    Phillips MI
    Braz J Med Biol Res; 2000 Jun; 33(6):715-21. PubMed ID: 10829100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense inhibition of AT1 receptor in vascular smooth muscle cells using adeno-associated virus-based vector.
    Mohuczy D; Gelband CH; Phillips MI
    Hypertension; 1999 Jan; 33(1 Pt 2):354-9. PubMed ID: 9931129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant adeno-associated virus-mediated delivery of antisense angiotensin II receptor 1 gene attenuates hypertension development.
    Li XG; Yan JT; Xu XZ; Wang JN; Cheng LM; Wang T; Zuo P; Wang DW
    Acta Pharmacol Sin; 2007 Nov; 28(11):1737-45. PubMed ID: 17959024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transient decrease in high blood pressure by in vivo transfer of antisense oligodeoxynucleotides against rat angiotensinogen.
    Tomita N; Morishita R; Higaki J; Aoki M; Nakamura Y; Mikami H; Fukamizu A; Murakami K; Kaneda Y; Ogihara T
    Hypertension; 1995 Jul; 26(1):131-6. PubMed ID: 7541778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antisense inhibition of the renin-angiotensin system in brain and peripheral organs.
    Mohuczy D; Phillips MI
    Methods; 2000 Nov; 22(3):197-209. PubMed ID: 11071815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time course of inhibition of hypertension by antisense oligonucleotides targeted to AT1 angiotensin receptor mRNA in spontaneously hypertensive rats.
    Gyurko R; Tran D; Phillips MI
    Am J Hypertens; 1997 May; 10(5 Pt 2):56S-62S. PubMed ID: 9160782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of hypertension by peripheral administration of antisense oligodeoxynucleotides.
    Wielbo D; Simon A; Phillips MI; Toffolo S
    Hypertension; 1996 Jul; 28(1):147-51. PubMed ID: 8675256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The potential role of antisense oligodeoxynucleotide therapy for cardiovascular disease.
    Phillips MI; Galli SM; Mehta JL
    Drugs; 2000 Aug; 60(2):239-48. PubMed ID: 10983731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene therapy for hypertension: antisense inhibition of the renin-angiotensin system.
    Phillips MI; Kimura B
    Methods Mol Med; 2005; 108():363-79. PubMed ID: 16028695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous injection with antisense oligodeoxynucleotides against angiotensinogen decreases blood pressure in spontaneously hypertensive rats.
    Makino N; Sugano M; Ohtsuka S; Sawada S
    Hypertension; 1998 May; 31(5):1166-70. PubMed ID: 9576130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo effects of partial phosphorothioated AT1 receptor antisense oligonucleotides in spontaneously hypertensive and normotensive rats.
    Piegari E; Galderisi U; Berrino L; Di Bernardo G; Cipollaro M; Esposito F; Rossi F; Cascino A
    Life Sci; 2000 Apr; 66(21):2091-9. PubMed ID: 10823348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous angiotensinogen antisense in AAV-based vector decreases hypertension.
    Tang X; Mohuczy D; Zhang YC; Kimura B; Galli SM; Phillips MI
    Am J Physiol; 1999 Dec; 277(6):H2392-9. PubMed ID: 10600860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.